IL5 and asthma: Inhibition of IL-5 with neutralizing antibodies is protective against a variety of eosinophilic diseases and indeed humanized anti-IL-5 antibodies have recently been approved for clinical use in patients with asthma, particularly those with the eosinophilic endotype12–16.